IL142375A0 - Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent - Google Patents

Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Info

Publication number
IL142375A0
IL142375A0 IL14237599A IL14237599A IL142375A0 IL 142375 A0 IL142375 A0 IL 142375A0 IL 14237599 A IL14237599 A IL 14237599A IL 14237599 A IL14237599 A IL 14237599A IL 142375 A0 IL142375 A0 IL 142375A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
active agent
sustained release
pharmaceutically active
release pharmaceutical
Prior art date
Application number
IL14237599A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL142375(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL142375A0 publication Critical patent/IL142375A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14237599A 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent IL142375A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Publications (1)

Publication Number Publication Date
IL142375A0 true IL142375A0 (en) 2002-03-10

Family

ID=22627919

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14237599A IL142375A0 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
IL142375A IL142375A (en) 1998-10-14 2001-04-02 A pharmaceutical preparation with a controlled release and a method for releasing a pharmacologically active substance

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142375A IL142375A (en) 1998-10-14 2001-04-02 A pharmaceutical preparation with a controlled release and a method for releasing a pharmacologically active substance

Country Status (30)

Country Link
EP (1) EP1121116B1 (xx)
JP (2) JP2002527388A (xx)
KR (1) KR100517090B1 (xx)
CN (1) CN1196481C (xx)
AR (2) AR020780A1 (xx)
AT (1) ATE382345T1 (xx)
AU (1) AU765475B2 (xx)
BR (1) BR9911648A (xx)
CA (1) CA2346868C (xx)
CO (1) CO5140079A1 (xx)
CY (1) CY1107874T1 (xx)
DE (1) DE69937891T2 (xx)
DK (1) DK1121116T3 (xx)
ES (1) ES2297936T3 (xx)
HK (1) HK1040920B (xx)
HU (1) HUP0104268A3 (xx)
ID (1) ID29350A (xx)
IL (2) IL142375A0 (xx)
MY (1) MY121105A (xx)
NO (1) NO327285B1 (xx)
NZ (1) NZ511010A (xx)
PE (1) PE20001110A1 (xx)
PL (1) PL198850B1 (xx)
PT (1) PT1121116E (xx)
RU (1) RU2259826C2 (xx)
SK (2) SK286595B6 (xx)
TR (1) TR200101088T2 (xx)
TW (1) TW577738B (xx)
WO (1) WO2000021525A2 (xx)
ZA (1) ZA200103001B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001093859A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
ATE361060T1 (de) * 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2004024184A1 (ja) * 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
CA2520197A1 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
JP2009527577A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム医薬組成物
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
SG11201505352RA (en) * 2013-01-09 2015-08-28 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
AU2018378348A1 (en) 2017-12-05 2020-06-18 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CA3112205A1 (en) 2018-09-25 2020-04-02 Ponce De Leon Health Designated Activity Company Process for making calcium alpha-ketoglutarate
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
PL186907B1 (pl) * 1995-12-22 2004-03-31 Kowa Co Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
AU765475B2 (en) 2003-09-18
CA2346868A1 (en) 2000-04-20
NO20011695L (no) 2001-05-30
PT1121116E (pt) 2008-03-12
TR200101088T2 (tr) 2001-10-22
CA2346868C (en) 2008-09-09
ZA200103001B (en) 2002-07-11
RU2259826C2 (ru) 2005-09-10
DK1121116T3 (da) 2008-05-13
AR020780A1 (es) 2002-05-29
SK286596B6 (sk) 2009-01-07
HK1040920A1 (en) 2002-06-28
ES2297936T3 (es) 2008-05-01
NO20011695D0 (no) 2001-04-04
EP1121116B1 (en) 2008-01-02
JP4938383B2 (ja) 2012-05-23
BR9911648A (pt) 2001-03-20
JP2006298945A (ja) 2006-11-02
IL142375A (en) 2012-01-31
CY1107874T1 (el) 2013-06-19
JP2002527388A (ja) 2002-08-27
PL348109A1 (en) 2002-05-06
HK1040920B (zh) 2005-07-29
KR20010080156A (ko) 2001-08-22
PE20001110A1 (es) 2000-11-01
EP1121116A2 (en) 2001-08-08
SK5092001A3 (en) 2001-09-11
CN1328454A (zh) 2001-12-26
AR069281A2 (es) 2010-01-13
ATE382345T1 (de) 2008-01-15
AU6090999A (en) 2000-05-01
WO2000021525A2 (en) 2000-04-20
HUP0104268A3 (en) 2002-06-28
DE69937891T2 (de) 2008-12-11
ID29350A (id) 2001-08-23
DE69937891D1 (de) 2008-02-14
SK286595B6 (sk) 2009-01-07
CN1196481C (zh) 2005-04-13
NO327285B1 (no) 2009-06-02
KR100517090B1 (ko) 2005-09-27
CO5140079A1 (es) 2002-03-22
MY121105A (en) 2005-12-30
TW577738B (en) 2004-03-01
WO2000021525A3 (en) 2000-08-10
HUP0104268A2 (hu) 2002-04-29
NZ511010A (en) 2003-10-31
PL198850B1 (pl) 2008-07-31

Similar Documents

Publication Publication Date Title
IL142375A0 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
EP1286662A4 (en) TABLETS AND METHODS FOR MODIFIED RELEASE OF HYDROPHILIC AGENTS OR OTHER AGENTS
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
IL148168A0 (en) Pharmaceutical composition of nateglinide and another antidiabetic agent
PL342162A1 (en) Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent
PL347634A1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1337249A4 (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
IL141155A0 (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
EP1117357A4 (en) METHODS AND DEVICES FOR IMPROVING THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS
EP1171117A4 (en) LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
PL336296A1 (en) Composition of retarded active substance release and method of obtaining them
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
HUP0202654A3 (en) Pharmaceutical compositions of fibrinolytic agent and process for preparation thereof
PL344564A1 (en) Matrix tablet enabling prolonged release of trimethiazidine after oral administration and method of making such tablet
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
EP1154997A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
PL339349A1 (en) Therapeutic agent preparation of controllable active substance release
IL139512A0 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates
PL337868A1 (en) Oral preparation of controllable analgesic agent release
IL126892A0 (en) Pharmaceutical compositions for the sustained release of insoluble active principles
IL136142A0 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
GB9904485D0 (en) Method for protecting and/or controlled release of active ingredient
PL350054A1 (en) Sustained release salts of pharmaceutically active peptides and their production
EP0959887A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USING THE SAME